Targeting prostate cancer with radiolabelled bombesins

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The fact that a number of common human tumours, including those of breast and prostate, express increased levels of the gastrin-releasing peptide receptor (GRP-R) means that this receptor is a potential target for peptide receptor mediated scintigraphy and targeted radionuclide therapy. Although clinical application is yet in its infancy, there is a considerable literature on preclinical studies aimed at developing suitable radioligands for potential clinical application. This brief review provides an overview of this research and also describes some of the limited clinical studies that have been published.

Related collections

Most cited references 74

Record: found
Abstract: found
Article: not found

Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation.

R. Markwalder, J Reubi (1999)

Bombesin-like peptides such as gastrin-releasing peptide (GRP) have been shown to play a role in cancer as autocrine growth factors that stimulate tumor growth through specific receptors. To search for potential clinical indications for GRP analogues, it is important to identify human tumor types expressing sufficient amounts of the respective receptors. In the present study, we have evaluated the expression of GRP receptors in human nonneoplastic and neoplastic prostate tissues using in vitro receptor autoradiography on tissue sections with 125I-Tyr4-bombesin as radio-ligand. GRP receptors were detected, often in high density, in 30 of 30 invasive prostatic carcinomas and also in 26 of 26 cases of prostatic intraepithelial proliferative lesions, corresponding mostly to prostatic intraepithelial neoplasias. Well-differentiated carcinomas had a higher receptor density than poorly differentiated ones. Bone metastases of androgen-independent prostate cancers were GRP receptor-positive in 4 of 7 cases. Conversely, GRP receptors were identified in only a few hyperplastic prostates and were localized in very low density in glandular tissue and, focally, in some stromal tissue. In all of the cases, the receptors corresponded to the GRP receptor subtype of bombesin receptors, having high affinity for GRP and bombesin and lower affinity for neuromedin B. These data demonstrate a massive GRP receptor overexpression in prostate tissues that are neoplastically transformed or, like prostatic intraepithelial neoplasias, are in the process of malignant transformation. GRP receptors may be markers for early molecular events in prostate carcinogenesis and useful in differentiating prostate hyperplasia from prostate neoplasia Such data may not only be of biological significance but may also provide a molecular basis for potential clinical applications such as GRP-receptor scintigraphy for early tumor diagnosis, radiotherapy with radiolabeled bombesin-like peptide analogues, and chemotherapy with cytotoxic bombesin analogues.

0 comments Cited 73 times – based on 0 reviews      Review now

Record: found
Abstract: not found
Article: not found

99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals.

Jodi Edwards, Stephanie S. Liu (1999)

0 comments Cited 51 times – based on 0 reviews      Review now

Record: found
Abstract: found
Article: not found

Bombesin receptor subtypes in human cancers: detection with the universal radioligand (125)I-[D-TYR(6), beta-ALA(11), PHE(13), NLE(14)] bombesin(6-14).

Jacqueline Schmuckli-Maurer, Jean Claude Reubi, Dominik J. Schaer … (2002)

Bombesin and bombesin receptors have been shown to play a role in cancer. Whereas the gastrin-releasing peptide (GRP) receptor is a bombesin receptor subtype frequently expressed by tumors, the other three subtypes, the neuromedin B (NMB), BB3, and BB4 receptors, have been poorly investigated in human tissues. We investigated 161 human tumors for their bombesin receptor subtype expression using in vitro receptor autoradiography with the universal bombesin radioligand (125)I-[D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)]bombesin(6-14) in displacement experiments with unlabeled GRP, bombesin, NMB, and [D-Tyr(6), beta-Ala(11), Phe(13), Nle(14)]bombesin(6-14). The distinct rank order of potencies of these analogues for each receptor subtype allows us to identify the predominant subtype expressed by each tumor. Twelve of 12 prostate cancers, 41 of 57 breast cancers, and 5 of 5 gastrinomas expressed predominantly GRP receptors; 11 of 24 intestinal, 1 of 26 bronchial, and 1 of 1 thymic carcinoids had preferentially NMB receptors; 9 of 26 bronchial carcinoids, 1 large cell neuroendocrine lung carcinoma, and 4 of 9 small cell lung carcinomas had preferentially BB3 receptors, whereas 3 of 9 small cell lung carcinomas had GRP receptors. Renal cell carcinomas had GRP receptors in 6 of 16 cases and BB3 receptors in 4 of 16 cases. Finally, 2 of 10 Ewing sarcomas had BB3 receptors. In situ hybridization detected BB3 receptor mRNA in neuroendocrine tumors expressing the BB3 protein. This is the first study detecting the proteins of BB3, NMB, and GRP receptors in a group of human tumors using differential binding techniques. Particularly relevant is the BB3 expression in lung carcinoids and other neuroendocrine lung tumors, whereas gastrointestinal carcinoids preferably express NMB receptors. These tumors may be targets for diagnostic and radiotherapeutic applications of subtype-selective bombesin analogues.

0 comments Cited 44 times – based on 0 reviews      Review now

All references

Author and article information

Journal

Journal ID (nlm-ta): Cancer Imaging

Journal ID (publisher-id): CI

Title: Cancer Imaging

Publisher: e-MED

ISSN (Print): 1740-5025

ISSN (Electronic): 1470-7330

Publication date Collection: 2006

Publication date (Electronic): 8 November 2006

Volume: 6

Issue: 1

Pages: 153-157

Affiliations

[* ]Institute of Radioisotopes – Radiodiagnostic Products, NCSR ‘Demokritos’, Athens, Greece

[† ]Centre for Cancer Imaging, Barts and the London Queen Mary School of Medicine and Dentistry, London, UK

Author notes

Corresponding address: Prof Stephen J Mather, Department of Nuclear Medicine, St Bartholomew’s Hospital, London EC1A 7BE, UK. Email: Stephen.Mather@ 123456cancer.org.uk

Article

Other ID: CI60025 Other ID: jCI.v6.i1.pg153 Other ID: ci060025

DOI: 10.1102/1470-7330.2006.0025

PMC ID: 1693771

PubMed ID: 17098646

SO-VID: c1ac1e26-7fd2-4aa0-adfa-619e71cf225b

History

Date accepted : 30 August 2006

Comments

Comment on this article

Cited by 9

See all cited by

Most referenced authors 490

See all reference authors